Our top pick for
Building a portfolio
Novavax, Inc (NVAX) is a leading biotechnology business based in the US. It opened the day at USD$170.67 after a previous close of USD$173.75. During the day the price has varied from a low of USD$165.62 to a high of USD$177.41. The latest price was USD$173.32 (25 minute delay). Novavax is listed on the NASDAQ and employs 792 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, Novavax's share price has had significant positive movement.
Its last close price was USD$173.32, which is 95.55% up on its pre-crash value of USD$7.72 and 2,668.69% up on the lowest point reached during the March crash when the shares fell as low as USD$6.26.
If you had bought USD$1,000 worth of Novavax shares at the start of February 2020, those shares would have been worth USD$1.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$25.00.
|52-week range||USD$16.41 - USD$331.68|
|50-day moving average||USD$194.24|
|200-day moving average||USD$152.75|
|Wall St. target price||USD$300.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-8.60|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-04-08)||N/A|
|1 month (2021-03-19)||-24.07%|
|3 months (2021-01-15)||N/A|
|6 months (2020-10-15)||N/A|
|1 year (2020-04-15)||N/A|
|2 years (2019-04-15)||N/A|
|3 years (2018-04-15)||N/A|
|5 years (2016-04-15)||N/A|
|Revenue TTM||USD$475.6 million|
|Gross profit TTM||USD$-271,429,000|
|Return on assets TTM||-29.48%|
|Return on equity TTM||-189.6%|
|Market capitalisation||USD$14.9 billion|
TTM: trailing 12 months
There are currently 4.3 million Novavax shares held short by investors – that's known as Novavax's "short interest". This figure is 13.2% down from 4.9 million last month.
There are a few different ways that this level of interest in shorting Novavax shares can be evaluated.
Novavax's "short interest ratio" (SIR) is the quantity of Novavax shares currently shorted divided by the average quantity of Novavax shares traded daily (recently around 3.8 million). Novavax's SIR currently stands at 1.13. In other words for every 100,000 Novavax shares traded daily on the market, roughly 1130 shares are currently held short.
However Novavax's short interest can also be evaluated against the total number of Novavax shares, or, against the total number of tradable Novavax shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novavax's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Novavax shares in existence, roughly 60 shares are currently held short) or 0.0583% of the tradable shares (for every 100,000 tradable Novavax shares, roughly 58 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novavax.
Find out more about how you can short Novavax stock.
We're not expecting Novavax to pay a dividend over the next 12 months.
Novavax's shares were split on a 1:20 basis on 9 May 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novavax shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Novavax shares which in turn could have impacted Novavax's share price.
Over the last 12 months, Novavax's shares have ranged in value from as little as $16.41 up to $331.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novavax's is 1.4727. This would suggest that Novavax's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Novavax, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.